Free Trial
NASDAQ:HUMA

Humacyte (HUMA) Stock Price, News & Analysis

$6.99
+0.54 (+8.37%)
(As of 07/12/2024 ET)
Today's Range
$6.41
$7.00
50-Day Range
$4.51
$9.10
52-Week Range
$1.96
$9.97
Volume
3.47 million shs
Average Volume
3.36 million shs
Market Capitalization
$832.37 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00

Humacyte MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
14.4% Upside
$8.00 Price Target
Short Interest
Bearish
8.97% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.63mentions of Humacyte in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$12.46 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.95) to ($0.73) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.48 out of 5 stars

Medical Sector

714th out of 917 stocks

Biological Products, Except Diagnostic Industry

123rd out of 152 stocks

HUMA stock logo

About Humacyte Stock (NASDAQ:HUMA)

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

HUMA Stock Price History

HUMA Stock News Headlines

Humacyte, Inc. (NASDAQ:HUMA) Short Interest Update
The #1 A.I. Crypto You Don’t Own (YET!)
Artificial Intelligence has revolutionized the way we consume media and entertainment… And the A.I. wave has also created MASSIVE opportunities for savvy investors. One recent move stands out above all others: recently surfaced investments from three major media companies.
Humacyte (NASDAQ:HUMA) Shares Gap Up to $4.80
The #1 A.I. Crypto You Don’t Own (YET!)
Artificial Intelligence has revolutionized the way we consume media and entertainment… And the A.I. wave has also created MASSIVE opportunities for savvy investors. One recent move stands out above all others: recently surfaced investments from three major media companies.
Benchmark Co. Keeps Their Buy Rating on Humacyte (HUMA)
Q1 2024 Humacyte Inc Earnings Call
See More Headlines
Receive HUMA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Humacyte and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/10/2024
Today
7/13/2024
Next Earnings (Estimated)
8/12/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:HUMA
Fax
N/A
Employees
183
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.00
High Stock Price Target
$15.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+14.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-110,780,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.57 million
Book Value
$0.13 per share

Miscellaneous

Free Float
91,576,000
Market Cap
$832.37 million
Optionable
Optionable
Beta
1.51
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Laura E. Niklason M.D. (Age 61)
    Ph.D., Founder, President, CEO & Director
    Comp: $899.25k
  • Mr. Dale A. Sander (Age 64)
    CFO, Chief Corporate Development Officer & Treasurer
    Comp: $704.33k
  • Dr. Heather Ledbetter Prichard Ph.D. (Age 46)
    Chief Operating Officer
    Comp: $647.78k
  • Dr. Juliana L. Blum Ph.D.
    Co-Founder & Executive Advisor
  • Ms. Sabrina Osborne
    Executive Vice President of Business Strategy & People
  • Mr. William John Scheessele (Age 52)
    Chief Commercial Officer
  • Dr. Shamik J. Parikh M.D. (Age 51)
    Chief Medical Officer
    Comp: $514.72k
  • Mr. Harold Alterson
    Senior Vice President of Quality
  • Dr. Yang Cao M.D. (Age 58)
    Ph.D., Chief Regulatory Officer

HUMA Stock Analysis - Frequently Asked Questions

How have HUMA shares performed this year?

Humacyte's stock was trading at $2.84 at the start of the year. Since then, HUMA shares have increased by 146.1% and is now trading at $6.99.
View the best growth stocks for 2024 here
.

How were Humacyte's earnings last quarter?

Humacyte, Inc. (NASDAQ:HUMA) announced its quarterly earnings data on Friday, May, 10th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by $0.06.

How do I buy shares of Humacyte?

Shares of HUMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:HUMA) was last updated on 7/13/2024 by MarketBeat.com Staff

From Our Partners